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ABSTRACT
Objectives: At least 30% of young people with
chronic fatigue syndrome/myalgic encephalomyelitis
(CFS/ME) also have symptoms of depression. This
systematic review aimed to establish which treatment
approaches for depression are effective and whether
comorbid depression mediates outcome.
Setting: A systematic review was undertaken. The
search terms were entered into MEDLINE, EMBASE,
PsycInfo and the Cochrane library.
Participants: Inclusion and exclusion criteria were
applied to identify relevant papers. Inclusion criteria
were children age <18, with CFS/ME, defined using
CDC, NICE or Oxford criteria, and having completed a
valid assessment for depression.
Results: 9 studies were identified which met the
inclusion criteria, but none specifically tested
treatments for paediatric CFS/ME with depression and
none stratified outcome for those who were depressed
compared with those who were not depressed. There is
no consistent treatment approach for children with
CFS/ME and comorbid depression, although cognitive–
behavioural therapy for CFS/ME and a multicomponent
inpatient programme for CFS/ME have shown some
promise in reducing depressive symptoms. An antiviral
medication in a small scale, retrospective, uncontrolled
study suggested possible benefit.
Conclusions: It is not possible to determine what
treatment approaches are effective for depression in
paediatric CFS/ME, nor to determine the impact of
depression on the outcome of CFS/ME treatment.
Young people with significant depression tend to have
been excluded from previous treatment studies.
BACKGROUND
Chronic fatigue syndrome (CFS)/myalgic
encephalomyelitis (ME) in young people are
common and disabling. It has a signiﬁcant
impact on a young person’s functioning,
including school attendance1 with approxi-
mately half of young people with CFS/ME
being bedbound at some stage of their
illness, and missing, on average, 1 year of
school.2 The estimated prevalence of paediat-
ric CFS/ME is between 1% and 2.4%
depending on the methodology and diagnos-
tic criteria used.3 4 There are a number of
recognised and widely accepted diagnostic
criteria for CFS/ME, including the Centers
for Disease Control and Prevention (CDC)
criteria, also known as the Fukuda deﬁnition,5
the Oxford6 criteria and the criteria deﬁned
by the National Institute for Health and Care
Excellence7 (table 1). In summary, to meet a
diagnosis of CFS/ME, these criteria require
the presence of recurrent or persistent fatigue
which is debilitating, has lasted for at least 37
or 6 months5 in duration but is not lifelong, is
not explained by ongoing exertion, is not alle-
viated by rest, is not explained by other condi-
tions (including depression) and has a
substantial impact on activity.8
Although the diagnosis of CFS/ME cannot
be made if signiﬁcant depression is the cause
of the fatigue, a diagnosis can be made in
the presence of comorbid depression which
does not fully explain the disabling fatigue.
At least 30% of children with CFS/ME have
symptoms indicative of depression9 10 which
is signiﬁcantly higher than the prevalence of
depression in the healthy population of
Strengths and limitations of this study
▪ A systematic approach was taken, which aimed
to identify the highest quality evidence available.
▪ Two reviewers independently completed the
screening and data extraction process, and a
third reviewer arbitrated when there was a lack of
consensus.
▪ Articles in foreign languages were included so
these results have wide applicability.
▪ Grey literature and unpublished material were not
included.
▪ A formal quality assessment of the observational
studies was not undertaken.
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Table 1 Diagnostic criteria for CFS/ME
Oxford criteria6 CDC criteria5 Canadian criteria35 NICE criteria7
Principal
symptom
Fatigue Fatigue Fatigue Fatigue
Other
symptoms
Myalgia, mood, sleep disturbance At least four of: sore throat, tender
lymph nodes, muscle pain, joint
pain, headaches, unrefreshing
sleep, postexertional malaise,
impaired memory or concentration
Postexertional malaise and/or
postexertional fatigue, unrefreshing
sleep or sleep disturbance, pain.
Cognitive dysfunction
Malaise, headaches, sleep
disturbances, difficulties with
concentration and muscle pain and/
or joint pain, painful lymph nodes,
sore throat, dizziness and/or nausea,
and palpitations with no identifiable
heart problem
Onset Definite onset but not life long Of new or definite onset
(not lifelong)
Not stated New, persistent and/or recurrent
Duration Minimum of 6 months, for ≥50% of
the time
≥6 months. Persistent or relapsing ≥3 months in a child or young
person. Persistent or reoccurring
≥3 months in a child or young
person
Impact on
functioning
Severe, disabling. Impacts on physical
and mental functioning
Results in a substantial reduction in
occupational, educational, social or
personal functioning
Results in substantial reduction in
previous levels of educational, social
and personal functioning
Substantial reduction in activity
levels
Exclusions Medical conditions known to result in
ongoing fatigue. Current diagnosis of
schizophrenia, manic depressive
illness, substance abuse, eating
disorder or organic brain disease
Fatigue is not substantially
alleviated by rest, and is not the
result of ongoing exertion. Fatigue
is clinically evaluated and
unexplained
Fatigue is clinically evaluated and
unexplained.
Current psychiatric conditions that
may explain the presence of chronic
fatigue, including schizophrenia or
psychotic disorders, bipolar disorder,
alcohol or substance abuse, anorexia
nervosa or bulimia nervosa and
depressive disorders
Fatigue not explained by other
conditions. The diagnosis of CFS/
ME should be reconsidered if none
of the following key features are
present: postexertional fatigue or
malaise, cognitive difficulties, sleep
disturbance and chronic pain
Subtypes Two syndromes:
Chronic fatigue syndrome (CFS)
Postinfectious fatigue syndrome
(PIFS)
None specified None specified None specified
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between 0.92%11 and 5%.12 Rates of depression in chil-
dren with CFS/ME are also higher than the rates of
depression in children with other chronic illnesses, for
example, cystic ﬁbrosis.13
The impact of having a comorbid mood disorder for
young people with CFS/ME is unclear. Depression
during adolescence in the normal population increases
the risk of subsequent depression, interpersonal difﬁ-
culties and suicide in adulthood.14 While the long-term
impact of depression in paediatric CFS/ME speciﬁcally
is not known, cross-sectional studies have shown that
young people with CFS/ME and comorbid depression
are also more functionally disabled with worse fatigue
and more pain compared with those without depres-
sion.10 Comorbid depression in adults with CFS/ME
has been associated with a worse prognosis in some
clinical trials,15–19 but not in others.20–22 It is plausible
that comorbid paediatric depression in CFS/ME may
impact on treatment outcome, but this has yet to be
investigated.
Despite the recognised comorbidity and clear guid-
ance that children/young people with CFS/ME should
be screened and treated for depression,7 23 little is known
about the efﬁcacy and effectiveness of treatments for paedi-
atric CFS/ME with comorbid depression, and the impact
of the comorbid depression on recovery in CFS/ME. This
review aims to synthesise the existing evidence regarding
treatments for paediatric CFS/ME and comorbid depres-
sion by addressing the following questions:
1. What does the existing quantitative and qualitative lit-
erature tell us about treatment approaches for
depression in children with CFS/ME?
2. What is the outcome for children with CFS/ME who
are depressed compared with children who are not
depressed?
3. Does the outcome for children with CFS/ME and
comorbid depression vary between studies? Do par-
ticular treatment approaches have different outcomes?
METHODS
This review was registered on Prospero in February 2015,
registration numberCRD42015016813. The protocol is
available from http://www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42015016813.
Data sources and search strategy
The search strategy was designed to identify studies
examining depression in children or young people
(<18) with CFS/ME. MEDLINE, EMBASE, PsycInfo and
the Cochrane library were searched using search terms
developed in collaboration with an information special-
ist, designed to include the concepts ‘paediatric’, ‘CFS/
ME’ and ‘depression’ (details of search terms used avail-
able via http://dx.doi.org/10.15125/BATH-00127 and as
an online supplementary ﬁle). Citation lists of included
articles were hand-searched. Searches were carried out
in February 2015.
Study selection (inclusion and exclusion criteria)
Titles and abstracts of all articles were assessed for inclu-
sion by two reviewers (MEL and EAS) and conﬂicts dis-
cussed and resolved. Articles for possible inclusion were
reviewed in full and independently assessed for inclusion
by two reviewers (MEL and EAS), with all conﬂicts dis-
cussed and reviewed by a third reviewer (EC).
Inclusion criteria were children age <18, with CFS/
ME, deﬁned using CDC criteria,5 NICE7 or Oxford cri-
teria6 and having completed a valid assessment for
depression. This review was limited to studies with young
people (age <18 years) from 1991 onwards as this is
when the Oxford diagnostic criteria were published.
Studies of children who were fatigued due to other
causes and studies where chronic fatigue was not
deﬁned using one of the above criteria were excluded.
Studies of predominantly adult samples, where the data
were not separable for the <18 years, were also excluded.
Observational studies and clinical trials (randomised or
quasi-randomised) of children with CFS/ME where symp-
toms of depression were measured were included, as were
qualitative studies that reported on the treatment of
depression in children with CFS/ME. The outcome data
of interest was a change in depression and/or fatigue on
psychometrically validated assessments or validated diag-
nostic interviews, and studies presenting such data,
whether there was an intervention or not, were included.
Studies published in foreign languages were consid-
ered for inclusion. Where English language abstracts
were not available, or where the titles and abstracts indi-
cated that the study potentially met the inclusion criteria
and merited full-text review, the papers were translated
by native speakers to determine whether they met the
inclusion criteria. None of these papers met the full
inclusion criteria.
Data extraction and appraisal
Data extraction was completed independently by two
reviewers (MEL and EAS) using a purpose-designed
data extraction form, designed to capture the following
aspects: details of the setting of the study, how children
were recruited for the study, date of the study, partici-
pant characteristics (including age and gender), the
study design, the CFS/ME deﬁnition used, how depres-
sion was assessed, deﬁnition of response and the treat-
ment/intervention offered and outcomes.
Data synthesis
If sufﬁcient data were available, a meta-analysis would
have been conducted. The interventions were heteroge-
neous and the data were across a range of outcome mea-
sures which precluded this; therefore, a narrative review
was carried out.
Quality assessment
An assessment of study methodological quality was under-
taken for the included randomised controlled trials (RCTs)
using the Cochrane risk of bias assessment tool.24–26
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RESULTS
The systematic review identiﬁed 362 papers, with 1
further paper identiﬁed by hand searching reference
lists of included articles (ﬁgure 1). Of these 363 papers,
96 were included at full review, with the remainder
excluded at the screening stage. Of the 363 papers, 8
were foreign language articles (N=8; 2 French, 1
Catalan, 1 Russian, 2 Japanese, 1 Dutch, 1 Greek). Nine
studies met the inclusion criteria for the review.
Characteristics of included studies
Quality assessment
Of the nine studies that met the inclusion criteria, there
was one RCT.27 The Cochrane risk of bias assessment
tool was applied to this study (table 2). In summary,
there was a low risk of bias in some domains, but a high
risk of bias, or an uncertain risk of bias in others.
Study design
In summary, one included study was an RCT, which com-
pared two variations of the physical exercise intervention
of a multicomponent treatment programme in an
inpatient setting. The remaining eight studies were obser-
vational. Of these, six studies described outcome after
outpatient (three investigating CBT and one antiviral
medication) or inpatient (two studies investigating a mul-
ticomponent programme) treatment. Two more studies
were epidemiological studies. Further details of the study
designs are described below and in tables 3 (method-
ology) and 4 (ﬁndings). All studies, including the RCT,
had relatively small sample sizes, with the smallest includ-
ing 4 patients with CFS/ME, and the largest including 63
patients, of whom 52 were followed up.
Three studies evaluated the outcomes of CBT for
CFS/ME. Chalder et al28 administered a CBT-based out-
patient rehabilitation programme focused on remediat-
ing CFS/ME of up to 15 hourly face-to-face sessions.
Lloyd et al29 offered a less intensive intervention of
CBT-based guided self-help, focused on remediating
CFS/ME and also emotional symptoms where appropri-
ate, via six telephone sessions, of 30 min in duration, at
fortnightly intervals. Kawatani et al30 offered, on average,
ﬁve sessions of CBT over a 6-month period, combined
with pharmacotherapy (6 of the 19 patients were pre-
scribed SSRIs with or without other medications, 5
patients received an antihypotensive medication, mido-
drine hydrochloride, 4 received other medications and 4
received no medication).
Three studies, including an RCT, evaluated the out-
comes of a 4-week inpatient programme, focused on
Figure 1 Flow chart for systematic review based on PRISMA: Preferred Reporting Items for Systematic reviews and
Meta-Analyses.49
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graded exercise using hydrotherapy and physiotherapy,
school attendance and psychiatric input as required.
The RCT speciﬁcally compared two variations of physio-
therapy, aerobic exercise and resistance training, within
this programme. These studies were all small in sample
size, and due to the multidisciplinary and multicompo-
nent nature of the intervention (which included psycho-
logical therapy where indicated with no further details
speciﬁed about this), it is not possible to draw any con-
clusions about what the key components of the
approach may have been. The studies by Gordon and
Lubitz31 and Gordon et al27 are also limited by a lack of
follow-up data postdischarge.
One study was a retrospective case series of an antiviral
medication (outpatient) with a small sample size (N=15)
and variable length of intervention (ranging from 3 to
60 months). This study is further limited by the lack of a
comparator or control condition, and the uncontrolled
nature of this study, which does not report on other
interventions (eg, psychological input) which the
patient may have had concurrently. There are also con-
siderable missing data, particularly in regard to depres-
sion outcomes, which could bias the study ﬁndings.
Two studies did not offer any active intervention.
Rimes et al32 conducted a prospective study of a random
sample of British adolescents (n=842) from the general
population who were assessed at baseline and ∼4–
6 months later as part of the Ofﬁce for National Statistics
study of mental health in children. van de Putte et al33
undertook a longitudinal study to explore alexithymia
(the inability to identify and/or describe one’s emotions)
in paediatric CFS/ME. The research aimed to establish
whether alexithymia was a prognostic factor for recovery
from CFS/ME. As part of this study, they sought to estab-
lish the number of participants who had ‘recovered’ from
CFS/ME at 18 months (n=40), where recovery is deﬁned
as scoring within 2 SDs of the average fatigue score within
a population of healthy adolescents on the Subjective
Fatigue Subscale of the Checklist Individual Strength
(CIS-20). CFS/ME patients were compared with healthy
controls (n=36) at baseline. No differences in recovery
were evident between those adolescents with alexithymia
compared with those who were not alexithymic.
Only one study stratiﬁed their ﬁndings by depressed
versus non-depressed participants,34 and no studies
stratiﬁed their results by the severity of depression
(mild/moderate/severe).
Of the included studies, no studies were speciﬁcally
aimed at treating depression in the context of paediatric
CFS/ME. Thus, it appears that approaches commonly
used for CFS/ME are used for this subgroup of patients
without any particular adaptations. At the current time,
evidence of efﬁcacy or effectiveness for speciﬁc treat-
ments tailored to the subgroup of patients with depres-
sion in the context of paediatric CFS/ME does not exist.
The effectiveness of interventions in reducing depression
symptoms
Cognitive–behavioural therapy
The outcomes of CBT for CFS/ME varied across the
three studies included. Chalder et al28 found that, in
those 20 patients who completed treatment, depression,
fatigue, functioning and social adjustment signiﬁcantly
improved following their relatively intensive CBT pro-
gramme. Lloyd et al29 showed that a less intensive CBT
intervention resulted in a signiﬁcant change in fatigue
and school attendance, with improvements in depres-
sion, impairment and adjustment in the 52 patients
retained in the study at 6-month follow-up. However,
Kawatani et al30 assessed depressive symptomatology in
19 patients at baseline, and, on average, most of them
were in the mildly depressed range. In this group, they
did not ﬁnd a signiﬁcant improvement in fatigue at
6-month follow-up; mood was not reassessed. This study
applied the Jason et al35 diagnostic criteria, which
deﬁnes depressive disorders in the exclusionary criteria,
meaning that all those who were clinically depressed
would have been excluded from the study.
Multicomponent inpatient programme
All three studies27 31 36 evidence an improvement in
mood post-treatment (which applied to both arms of
Table 2 Risk of bias assessment for Gordon et al27 trial
Domain Description
Review author’s judgement
regarding risk of bias
Random sequence
generation
Drawing a piece of paper out of an envelope Low risk
Allocation concealment Unclear Uncertain risk of bias
Blinding of participants
and personnel
Not possible High risk
Blinding of outcome
assessment
Blinded assessor completed baseline and follow-up
assessments
Low risk
Incomplete outcome
data
Missing data points substituted with the last known measure for
each outcome. Intention to treat analysis using MANOVA
Low risk
Selective reporting Insufficient information Uncertain risk of bias
Other sources of bias Unclear Uncertain risk of bias
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Table 3 Summary of methodology and study design of included studies
Authors (year) Design
Number of
participants
CFS/ME
diagnostic
criteria
applied
Mean
age—years
(SD)
Measure of CFS/
ME
Measure of
depression Intervention
Was the
treatment
specifically
targeted at
or adapted
for
depression?
Was the
outcome of
treatment
stratified by
depressed vs
non-depressed?
Length of
follow-up
Chalder et al
(2002)
Observational
(outpatient)
23 Sharpe et al
(1991)*
(Range 11–
18, median
15)
CFS HADS CBT-based rehabilitation programme. Up to
15 hourly sessions
No No 6 months
Denborough et al
(2003)
Observational
(inpatient)
39 (19 at
6 months
follow-up)
Fukuda
et al (1994)
16.2 Chronic Fatigue
Illness Disability
Scale
FSS
BDI- 4-week inpatient programme, focused on
graded exercise using hydrotherapy and
physiotherapy.
No No 6 months
Gordon and Lubitz
(2009)
Observational
(inpatient)
16 Fukuda
et al (1994)
16 (1.28) FSS BDI 4-week inpatient programme, including graded
exercise therapy, psychological/psychiatric
support, attendance at school, recreation and
leisure intervention
No No Post-treatment
Gordon et al
(2010)
RCT (inpatient) 22 Fukuda
et al (1994)
16.2 (0.8) Exercise
tolerance
Muscle strength
FSS
BDI 4-week inpatient programme, including graded
exercise therapy, psychological/psychiatric
support, attendance at school. Aerobic training
compared with resistance training
No No Post-treatment
Henderson (2014) Observational
(outpatient,
retrospective
case series)
15 (14 at
follow-up)
Fukuda
et al (1994)
15.46 (3.11) Self-reported
improvement
FSS
Multidimensional
Fatigue Symptom
Inventory-Short
Form
CDI Valacyclovir (antiviral) medication, initially
500 mg two times a day, increasing after 2–
3 weeks. Duration of treatment ranged from 3
to 60 months (mean 27.9 months)
No Yes Varied—
post-treatment
Kawatani et al
(2011)
Observational
(outpatient)
19 Jason et al
(2006)
13.6 (0.7) CFS Zung
self-rating
depression
scale
CBT (average of 5 sessions over 6 months)
and pharmacotherapy
No No 6 months
Lloyd et al (2012) Observational
(outpatient)
63 (52 at
follow-up)
Sharpe et al
(1991)*
(Median 15) CFS Birleson
Depression
Scale
CBT via telephone based guided self-help—6
fortnightly sessions, 30mins duration
No No 6 months
Rimes et al (2007) Observational
(prospective,
community)
1 case of
CFS at time
1; 4 cases
CFS at
identified at
time 2
Fukuda
et al (1994)
(Range 11–
15)
Diagnostic
interview using
CDC criteria
Development
and
Well-being
Assessment
(interview)
None No No 4–6 months
van de Putte et al
(2007)
Observational
(prospective,
community)
40 at
baseline (36
at follow-up)
Fukuda
et al (1994)
16.0 (1.5) Subjective fatigue
subscale of
CIS-20
CDI at
baseline only
None No No 18 months
*In the studies using the Oxford criteria,6 it is unclear if the criteria for CFS or postinfectious fatigue syndrome (PIFS) were applied.
BDI, Beck Depression Inventory; CDI, Children’s Depression Inventory; CFS, Chalder Fatigue Scale; CIS-20, Checklist of Individual Strength; FSS, Fatigue Severity Scale; HADS, Hospital
Anxiety and Depression Scale.
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Table 4 Summary of outcomes for depressive symptoms and other relevant findings for included studies
Authors (year)
Measure of
depression Pretreatment
Post-treatment (unless
otherwise stated)
Statistical analysis of
change in depressive
symptomatology Summary of other relevant findings
Chalder et al
(2002)
HADS Mean 8.4 (IQR 5.7–11) 6-month follow-up
Mean 3 (IQR 3–5)
Wilcoxon signed-ranks test
−3.33 (two-tailed
significance 0.00)
All 20 treatment completers returned to school at
6 months follow-up, with 95% attending full time.
Depression significantly improved, as did social
adjustment
Denborough
et al (2003)
BDI Mean score 21 Mean score 15 Improvement p<0.001
Maintained at 6-month
follow-up (p<0.038)
On discharge, the mean depression score significantly
better than on admission. Also significant improvement in
Chronic Fatigue Illness Disability score and significant
decrease in FSS score (maintained at 6-month follow-up).
Achenbach/Youth Self-Report scores improved
significantly by discharge, but returned to above
admission levels at 6 months
Gordon and
Lubitz (2009)
BDI Mean 19.88 SD 8.62 Mean 11.44 SD 10.98 Paired t-test p value 0.001
sig 0.008
Significant improvement in BDI scores, Fatigue Severity
scores
Gordon et al
(2010)
BDI Resistance Arm
Pretreatment 20.9±11.3
Resistance arm
Post-treatment 14.2±10.0
Resistance arm
Difference −6.7±8.5
p=0.03
Significant improvement in BDI scores in both arms
Aerobic arm
Pretreatment 16.4±4.3
Aerobic arm
Post-treatment 12.2±6.7
Aerobic arm
Difference −4.2±4.8
p=0.002
Henderson
(2014)
CDI Mean score 14±2.83 (4 patients
with mood disorder, 16.8±1.92)
(11 patients without mood disorder
12.73±2.00)
Not stated Not reported All patients reported at least 80% self-rated improvement.
Significant reduction in FSS, MSFI (all subscales)
Kawatani et al
(2011)
Zung self-rating
depression scale
53.3±6.7 Not stated Not reported No significant change between baseline fatigue scores
and fatigue scores 6 m follow-up. Significant improvement
in performance status scores (self-reported impact on
functioning)
Lloyd et al
(2012)
Birleson
Depression
Scale
Baseline mean 13.38 (SD 4.76)
Pretreatment mean 12.91 (SD 5.57)
Post-treatment mean
10.98 (SD 5.35)
3-month follow-up mean
10.47 (SD 5.87)
6-month follow-up mean
9.22 (SD 5.36)
Multilevel modelling and
Wald tests
Treatment effect estimate at
6 months −3.69 (CI −5.17 to
−2.21)
Significance (two-tailed)
<0.001, effect size 0.78
Significant change in fatigue and school attendance, with
improvements in depression, impairment and adjustment
at 6 months
Rimes et al
(2007)
3 of 4 had at least 1 psychiatric
diagnosis at baseline
4 participants developed
CFS/ME at follow-up
(4–6 months)
Not reported Of the 4 participants who developed CFS/ME over the
follow-up period, 3 of 4 had at least 1 psychiatric
diagnosis at baseline, 3 had reported being ‘much more
tired and worn out than usual over the last month’ at time
1, 2 participants had frequent headaches at time 1, 1 also
had sleep problems and postexertional malaise at time 1
Van de Putte
et al (2007)
CDI Mean score at baseline 11.7 SD 6.1 Not stated Not reported 47% of adolescents ‘fully recovered’ (below score ie,
mean plus 2 SD of subjective fatigue distribution in health
adolescents).
BDI, Beck Depression Inventory; CDI, Children’s Depression Inventory; CFS, Chalder Fatigue Scale; CIS-20, Checklist of Individual Strength; FSS, Fatigue Severity Scale; HADS, Hospital
Anxiety and Depression Scale.
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the RCT), as well as a decrease in fatigue symptoms and
an improvement in functioning. Denborough et al36
showed that improvements in mood and fatigue are
maintained at 6-month follow-up, although parental-
rated and self-reported internalising problems had esca-
lated to above preadmission levels.
Antiviral medication
Henderson34 presents separate data on the post-
treatment scores of one subscale (emotional subscale) of
the Multidimensional Fatigue Symptom Inventory-Short
Form (MSFI-SF) for three patients who were diagnosed
with mood disorder when compared with seven partici-
pants who were not diagnosed with mood disorder (data
on this variable are missing for the remaining ﬁve
patients in the study) at assessment for treatment with
Valacyclovir. The length of treatment was variable (mean
27.9 months, range 3–60 months). Patients with a mood
disorder had a mean pretreatment score on the emo-
tional subscale of the MSFI of 13.00±6.16 and a mean
post-treatment score of 6.67±2.89, when compared with
patients without a mood disorder who had a pretreat-
ment score of 8.40±2.76 and a mean post-treatment
score of 1.5±1.6. Thus, depression symptoms decreased
in depressed and non-depressed patients over the course
of treatment. The remaining outcome data (self-rated
improvement, sleep, school performance, Fatigue
Severity Scale (FSS) scores, Fatigue Symptom Inventory
(FSI), and the fatigue, physical, mental and vigour sub-
scales of the MSFI) indicate signiﬁcant improvements
but are not stratiﬁed for the patients with and without
mood disorder.
Epidemiological studies. Rimes et al32 found that four
cases of CFS (according to CDC criteria) had developed
at 6-month follow-up in their population sample, three
of whom had had at least one psychiatric diagnosis at
baseline. Furthermore, three cases had reported being
more worn out than usual at time 1. There was also one
case of CFS diagnosed at baseline, although further
information about follow-up assessments is not separ-
ately available for this participant. van de Putte et al33
found that 47% of the 36 CFS/ME participants in their
longitudinal study had ‘recovered’ from CFS/ME at
18 months. At baseline, the CFS participants were found
to have signiﬁcantly higher depression scores on the
Children’s depression inventory (CDI) compared with
healthy controls, although the mean CDI score in the
CFS group still fell below the clinical cut-off for depres-
sive disorder. The outcomes in terms of recovery are not
stratiﬁed by depression severity.
DISCUSSION
Despite the high prevalence of depression in young
people with CFS/ME, there is little evidence about the
effectiveness of treatment for this population, and no
speciﬁcally adapted treatments have been trialled in this
population. In the studies included in this review, the
mean depression scores of the participants tended to be
below clinical cut-offs for depression pretreatment.
Thus, the samples in treatment studies, in which poten-
tial participants with signiﬁcant depression tend to be
excluded, do not appear to be representative of those in
clinical cohort studies, which have found a much higher
prevalence of depression in paediatric CFS/ME.10 In
these skewed samples, treatments aimed at remediating
CFS/ME, including CBT and a multicomponent
inpatient programme can result in improvements in
mood.
The strengths of this review are that a systematic
approach was taken, which sought to identify the highest
quality evidence available. Furthermore, two reviewers
independently completed the screening and data extrac-
tion procedures, with a third reviewer arbitrating when
there were differences of opinion. Articles in foreign lan-
guages were included so these results are not limited to
UK patients. However, a formal review of the quality of
the observational studies was not undertaken. This
would have been undertaken had those studies provided
signiﬁcant evidence to inform the review questions.
There is a lack of evidence to inform clinicians on
how best to help young people with CFS/ME who are
also low in mood, which is particularly surprising, given
that psychological models of the perpetuation of
chronic fatigue and disability include depression as part
of the maintenance cycle.37 Cognitive–behavioural
therapy, a multicomponent inpatient programme and
antiviral medication are the interventions used in the
included studies. CBT and the multicomponent
inpatient programme are broadly consistent with the
evidence-based guidelines from the National Institute
for Health and Care Excellence for the management
and treatment of CFS/ME7 and the management and
treatment of depression.38 The participants appear to
have beneﬁted from these interventions, including in
terms of mood, although the data do not allow compari-
sons to be made about whether those who were low in
mood beneﬁted less, as much, or possibly more than
those who were not low in mood. Larger sample sizes,
with more separable data about those participants who
are depressed versus those who are not depressed at
baseline would enable further conclusions to be drawn
about the effectiveness of these treatment approaches
for those with comorbid depression.
The lack of evidence about what treatment approach
is most effective with young people who have CFS/ME
and depression is further compounded by con-
tradictions within treatment approaches and the recom-
mendations for the disorders separately. Certain
recommendations made by NICE for the management
of CFS7 contradict the recommendations for the man-
agement of depression.38 For example, exercising for up
to three sessions, 45 min to an hour in duration of mod-
erate exercise, per week for 10–12 weeks39 may be effect-
ive for depression but could exacerbate symptoms in
patients with CFS/ME. Interventions for depression
8 Loades ME, et al. BMJ Open 2016;6:e012271. doi:10.1136/bmjopen-2016-012271
Open Access
group.bmj.com on June 13, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
such as behavioural activation would be limited by the
activity management approach advocated for managing
the CFS/ME.7 Furthermore, standard cognitive therapy
is cognitively demanding and may be beyond the cap-
acity of a young person who is cognitively limited in
attentional capacity and memory by fatigue.40
Similarly, the existing guidance and literature does not
provide any clear direction about using medication.
There is no known pharmacological treatment for CFS/
ME, although medications can be used for symptom
management.7 In the current review, one study used
antiviral medication with possible beneﬁt, although this
study was small scale, uncontrolled, retrospective and
had a variable length of follow-up, and therefore, it is
difﬁcult to draw any ﬁrm conclusions about the ﬁndings.
There is variable evidence about the efﬁcacy of anti-
depressant medications (SSRIs) in young people with a
primary diagnosis of depression; while antidepressants
can result in improvements to young people’s
mood,41 42 there are indications that SSRIs can increase
suicidality.43 The NICE38 recommendation is that medi-
cation should only be offered in combination with a spe-
ciﬁc psychological therapy unless the latter is declined.
Furthermore, there is currently no evidence about
whether antidepressant medication is beneﬁcial for
young people with CFS and depression; in the current
review, one paper did include SSRIs in combination with
CBT, but only for a proportion of their sample, and
outcome data were not separately presented for those
with depression.30 Additionally, there is mixed evidence
about the utility of antidepressant medication in adult
CFS populations with some studies ﬁnding no effect of
ﬂuoxetine in comparison to placebo44 45 and others
showing signiﬁcant improvements in CFS/ME and
depressive symptomatology in response to s-citalopram.46
It is notable that a number of the large-scale studies of
recovery in paediatric CFS/ME such as the Dutch trials
of FITNET47 48 do not appear to have speciﬁcally
included low mood or depression as an outcome vari-
able, although a broader well-being measure was
included in this study and a speciﬁc measure of depres-
sion was used at the baseline assessment to exclude the
most severely depressed young people. Furthermore, in
these trials, and a number of other trials of treatments
for paediatric CFS/ME, participants with psychiatric
diagnoses are excluded. Therefore, uncertainty
remains about how best to treat young people who
have diagnosable depression in the context of paediat-
ric CFS/ME.
CONCLUSION
This review has highlighted the relative lack of evidence
regarding effective treatment for paediatric CFS/ME
and comorbid depression. Given the levels of comorbid-
ity,10 impact on functioning and potentially, impact on
response to treatment, developing and trialling poten-
tially efﬁcacious and effective treatments for children
and young people with CFS/ME and depression is a pri-
ority for future research.
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